Day: October 7, 2025

Blog

OncoRock Therapeutics Launches at BioVentures 

We were excited to host the kickoff meeting for one of our newest startups, OncoRock Therapeutics, right here at BioVentures!   OncoRock is a biotechnology startup dedicated to transforming academic discoveries into impactful cancer treatments. Their capital-efficient model focuses on acquiring promising university assets, de-risking them through preclinical studies and early-phase clinical trials, and then partnering or licensing to pharma for late-stage development.  The company is advancing two first-in-class programs:  The founding team of OncoRock brings together deep expertise across oncology, immunology, and commercialization. Led by Alan Tackett, PhD (CEO), Brian Koss, PhD (COO), Nancy Rusch, PhD (CSO), Laura Hutchins, MD (CMO), and Sonet Weed, MS (CFO), the group has collectively secured over $100M in research funding and combines decades of experience in cancer research, clinical trials, drug development, and biotech entrepreneurship.   We’re thrilled to see their journey begin in our space and look forward to supporting their mission of bringing breakthrough therapies to patients with limited treatment options. 

Read More »